CATAPULT GROUP INTERNATIONAL LIMITED (CAT)
Share Price Analysis and Chart
Enter the company code or Name for stock analysis:
CAT - CATAPULT GROUP INTERNATIONAL LIMITED
FNArena Sector :
Medical Equipment & Devices
Year End: March
GICS Industry Group : Technology Hardware & Equipment
Debt/EBITDA: 2.06
Index: ALL-ORDS | ALL-TECH
FNArena Sector : Medical Equipment & Devices
Year End: March
GICS Industry Group : Technology Hardware & Equipment
Debt/EBITDA: 2.06
Catapult Group develops and sells wearable sensors to monitor and analyse athletic performance, including fitness and skill levels, injury risks and rehabilitation assistance. It listed on the ASX in 2014.
LAST PRICE | CHANGE +/- | CHANGE % | VOLUME |
---|---|---|---|
$3.39
22 Nov |
-0.110 OPEN $3.50 |
-3.14% HIGH $3.61 |
3,619,468 LOW $3.37 |
TARGET | |||||
|
OTHER COMPANIES IN THE SAME SECTOR | |||
4DX . AT1 . AYA . BB1 . BRN . CBL . CGS . CMP . COH . CSX . CU6 . CVB . CYC . EBR . EMV . EYE . FPH . IDX . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RMD . SOM . TRJ . UBI . VTI . |
FNARENA'S MARKET CONSENSUS FORECASTS
Title | FY25 Forecast |
FY26 Forecast |
---|---|---|
EPS (cps) | - 7.7 | xxx |
DPS (cps) | 0.0 | xxx |
EPS Growth | N/A | xxx |
DPS Growth | N/A | xxx |
PE Ratio | N/A | xxx |
Dividend Yield | 0.0% | xxx |
Div Pay Ratio(%) | N/A | xxx |
All estimates have been converted into AUD by FNArena at present FX values.
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title | 2018 | 2019 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|
EPS Basic | xxx | xxx | xxx | xxx | xxx | -10.6 |
DPS All | xxx | xxx | xxx | xxx | xxx | 0.0 |
Sales/Revenue | xxx | xxx | xxx | xxx | xxx | 152.1 M |
Book Value Per Share | xxx | xxx | xxx | xxx | xxx | 48.3 |
Net Operating Cash Flow | xxx | xxx | xxx | xxx | xxx | 45.4 M |
Net Profit Margin | xxx | xxx | xxx | xxx | xxx | -16.68 % |
EPS Basic
DPS All
Sales/Revenue
Book Value Per Share
Net Operating Cash Flow
Net Profit Margin
Title | 2018 | 2019 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|
Return on Capital Employed | xxx | xxx | xxx | xxx | xxx | -20.36 % |
Return on Invested Capital | xxx | xxx | xxx | xxx | xxx | -16.77 % |
Return on Assets | xxx | xxx | xxx | xxx | xxx | -10.23 % |
Return on Equity | xxx | xxx | xxx | xxx | xxx | -20.36 % |
Return on Total Capital | xxx | xxx | xxx | xxx | xxx | -15.10 % |
Free Cash Flow ex dividends | xxx | xxx | xxx | xxx | xxx | 29.5 M |
Return on Capital Employed
Return on Invested Capital
Return on Assets
Return on Equity
Return on Total Capital
Free Cash Flow ex dividends
Title | 2018 | 2019 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|
Short-Term Debt | xxx | xxx | xxx | xxx | xxx | 1 M |
Long Term Debt | xxx | xxx | xxx | xxx | xxx | 27 M |
Total Debt | xxx | xxx | xxx | xxx | xxx | 28 M |
Goodwill - Gross | xxx | xxx | xxx | xxx | xxx | 79 M |
Cash & Equivalents - Generic | xxx | xxx | xxx | xxx | xxx | 18 M |
Price To Book Value | xxx | xxx | xxx | xxx | xxx | 3.21 |
Short-Term Debt
Long Term Debt
Total Debt
Goodwill - Gross
Cash & Equivalents - Generic
Price To Book Value
Title | 2018 | 2019 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|
Capex | xxx | xxx | xxx | xxx | xxx | 41.1 M |
Capex % of Sales | xxx | xxx | xxx | xxx | xxx | 27.05 % |
Cost of Goods Sold | xxx | xxx | xxx | xxx | xxx | 148 M |
Selling, General & Admin. Exp & Other | xxx | xxx | xxx | xxx | xxx | 27 M |
Research & Development | xxx | xxx | xxx | xxx | xxx | - |
Investments - Total | xxx | xxx | xxx | xxx | xxx | 0 M |
Capex
Capex % of Sales
Cost of Goods Sold
Selling, General & Admin. Exp & Other
Research & Development
Investments - Total
EXPERT VIEWS
Display All Commentary
Sentiment Indicator
No. Of Recommendations
EXTRA COVERAGE
Display All Commentary
No. Of Recommendations
Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.
CAT STOCK CHART
FNArena News on CAT
1 |
Australian Broker Call *Extra* Edition – Nov 19, 2024Nov 19 2024 - Daily Market Reports |
2 |
FNArena Corporate Results Monitor – 15-11-2024Nov 15 2024 - Australia |
3 |
Weekly Ratings, Targets, Forecast Changes – 18-10-24Oct 21 2024 - Weekly Reports |
4 |
Rudi’s View: Growth Is Not A Dirty WordSep 25 2024 - Rudi's View |
5 |
FNArena Corporate Results Monitor – 07-06-2024Jun 07 2024 - Australia |
Latest Medical Equipment & Devices News
1 |
ResMed’s Bounce-Back CompleteOct 29 2024 - Australia |
2 |
Dr Boreham’s Crucible: Pro MedicusSep 04 2024 - Australia |
3 |
Pro Medicus: Don’t Stop Me NowAug 20 2024 - Technicals |
4 |
Dr Boreham’s Crucible: BlinklabMay 20 2024 - Small Caps |
5 |
ResMed Silences The DoubtersApr 29 2024 - Australia |
6 |
Dr Boreham’s Crucible: 4D MedicalApr 23 2024 - Small Caps |
7 |
Uptrend Resumed For ResMedMar 19 2024 - Technicals |
8 |
Dr Boreham’s Crucible: CochlearFeb 28 2024 - Australia |
9 |
Rudi Interviewed: Ongoing Potential In Technology & GrowthFeb 19 2024 - Rudi's View |
10 |
Dr Boreham’s Crucible: ArtryaFeb 15 2024 - Small Caps |